

(Rs. in crores except per share data)


Statement of Consolidated Financial Results for the Quarter ended 30-Jun-2021

Particulars	Quarter ended			Year ended
	30-Jun-2021 (Unaudited)	31-Mar-2021 (Audited) (Refer Note 4)	30-Jun-2020 (Unaudited)	31-Mar-2021 (Audited)
Revenue				
Net sales	2120	1915	2014	7886
Other operating income	14	22	42	119
Revenue from operations (net)	2134	1937	2056	8005
Other income	40	39	4	57
Total revenue	2174	1976	2060	8062
Expenses				
Cost of materials consumed	408	347	345	1421
Purchases of stock-in-trade	206	223	283	1005
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(26)	(74)	(93)	(279)
Employee benefits expense	385	341	373	1440
Finance costs	68	73	102	358
Depreciation amortisation and impairment expense	165	165	161	658
Other expenses	484	518	487	1933
Total expenses	1690	1593	1658	6536
Profit before tax	484	383	402	1526
Tax expense				
Current tax	88	105	82	334
Deferred tax (Refer Note 5)	66	(39)	(1)	(53)
Short provision of earlier periods	-	(7)	-	(7)
Total tax expense	154	59	81	274
Net profit for the period	330	324	321	1252
Attributable to :				
- Owners of the company	330	324	321	1252
- Non controlling Interest	-	-	-	-
Other comprehensive income				
Items that will not be reclassified subsequently to profit or loss	(4)	6	(6)	3
Income tax relating to items that will not be reclassified subsequently to profit or loss	2	(4)	2	(3)
Items that will be reclassified subsequently to profit or loss	(45)	28	32	156
Income tax relating to items that will be reclassified subsequently to profit or loss	11	(7)	(13)	(56)
Total other comprehensive income	(36)	23	15	100
Total comprehensive Income	294	347	336	1352
Attributable to :				
- Owners of the company	294	347	336	1352
- Non controlling Interest	-	-	-	-
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62
Other equity excluding revaluation reserves				5753
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):				
Basic	19.53	19.16	18.98	73.98
Diluted	19.53	19.16	18.98	73.98

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 27-Jul-2021. The auditor have carried out review of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The consolidated financial results include the financial results of fourteen wholly owned subsidiaries.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 The figures for the quarter ended 31-Mar-2021 is the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter of financial year, which were subject to limited review.
- 5 Deferred tax expense for the quarter ended 30-Jun-2021 includes Rs. 60 crores, relates to MAT credit utilisation.
- 6 The Group has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial results by the Board of Directors. The impact of Covid-19 may be different from what is estimated as at such date of approval of the financial results and the Group will continue to monitor any material changes to future economic conditions.
- 7 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED

**SAMIR
UTTAMLAL
MEHTA**  Digitally signed by
SAMIR UTTAMLAL
MEHTA
Date: 2021.07.27
16:38:53 +05'30'

Place : Croatia

Date : 27-Jul-2021

**SAMIR MEHTA
Executive Chairman**